Too much sorbitol may raise fatty liver disease risk, study finds
Excessive intake of sorbitol, a type of sugar naturally found in many fruits and used as a sugar substitute, may increase the risk of metabolic…
Steve Bryson, PhD, Science Writer—
Articles by Steve Bryson
New biomarkers may help detect pregnancy-linked liver complication
Levels of the metabolite palmitic acid and the protein ACSL1 in the bloodstream can accurately detect the presence and severity of intrahepatic cholestasis of…
New trial testing probiotic for reducing liver inflammation in PSC
Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…
Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data
Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…
Better to have Kasai surgery before liver transplant for biliary atresia
For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive fluid bile in the body…
Most recent liver stiffness test best predicts risk of PBC progression
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
Seladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…
Blood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
Large study finds risks of liver cancer low for certain PSC patients
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…
PPAR agonists effective in UDCA-resistant primary biliary cholangitis
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…